Acute Pain Market Overview
Acute pain is characterized as a sudden or urgent pain that will reduce or stop as healing progresses. The pain is caused by something specific such as surgery, burns, broken bones, labor and childbirth, etc., and is sharp in quality. Acute pain typically doesn’t last for more than 6 months. Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) are usually recommended as a first-line treatment for effective management of acute mild to moderate pain. On the other hand, topical NSAIDs are commonly taken for non-low-back, musculoskeletal injuries.
The rising introduction of new classes of analgesics including extended-release formulations and non-opioid pain relievers is expected to fuel the acute pain market growth. The growing public awareness regarding advanced pain management solutions and improvements in healthcare facilities are likely to support the development of the market. Moreover, the rising surgery rates, the increasing elderly population, and the presence of a favorable regulatory environment are poised to impact the market dynamics.
Key Findings
- The increasing number of surgical procedures and sports injuries combined with the growing elderly population who often undergo surgeries for age-related conditions are the key drivers of the market growth.
- The rise in new acute pain management drugs and device approvals by regulatory bodies is a significant market trend. For instance, in September 2024 , MedTech company Zynex Inc's TensWave device received FDA clearance for treating acute pain through TENS (Transcutaneous Electrical Nerve Stimulation) therapy.
- The shift towards alternatives to opioid analgesics due to concerns over addiction and the development of targeted drug delivery systems that minimize systemic exposure is projected to elevate the market value during the forecast period.
Acute Pain Market Demand Drivers
The rising burden of acute pain conditions owing to the increasing cases of surgical procedures, sports injuries, and various diseases that cause sudden, intense pain is one of the primary drivers of the market, propelling the demand for acute pain medications. The growing volume of medical and surgical interventions such as orthopedic surgeries, cesarean sections, and elective surgeries, is increasing the need for effective postoperative pain management. Postoperative pain poses a major global health challenge and is a common type of acute pain. The prevalence of acute postoperative pain is estimated to be 88.5% and is reported to be the highest in the departments of general surgery and orthopedic-traumatology. Thus, the increasing incidence of acute pain cases is anticipated to augment the market demand in the coming years.
Acute Pain Market Segmentation Analysis
The Drug Class Segment is Anticipated to Witness Significant Growth in the Forecast Period
Based on the drug class, the market segmentation comprises NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, analgesics, and others. The NSAIDs (non-steroidal anti-inflammatory drugs) segment covers a significant market share owing to the high efficacy of this drug class in the treatment of mild to moderate acute pain, including pain associated with inflammation, such as sprains, muscle strains, and post-surgical pain. The affordability and widespread accessibility of these drugs also bolsters the demand for this segment. However, long-term use of NSAIDs for the management of pain and inflammation can lead to gastrointestinal side effects and cardiovascular risks.
The market report also offers insights based on form, indication, distribution channel, and region.
Acute Pain Market: Competitive Landscape
- In August 2024 , American biopharma company Vertex Pharmaceuticals Incorporated received New Drug Application approval for suzetrigine, a novel class of analgesics, from the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe acute pain.
- In February 2024 , SPR Therapeutics, a medical device company specializing in neurostimulation technology, secured USD 85 million in equity financing, to support robust commercial expansion of its SPRINT® PNS System which can help in the treatment of acute post-operative pain.
- Other players involved in the market include Pfizer Inc., Abbott, GSK plc, Novartis AG, Purdue Pharma LP, Sun Pharmaceutical, Eli Lilly and Company, Intas Pharma, Johnson & Johnson Services Inc., and Sanofi.
Acute Pain Market Analysis by Region
The United States is Projected to Lead the Market Share
The market report offers insight into various geographical locations, including the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States represents a major market which can be attributed to the rising burden of acute pain conditions and the presence of a well-established healthcare. The high adoption rate of advanced pain management therapies and the greater accessibility of acute pain solutions in the region further support market growth. Moreover, the rising healthcare expenditure and increasing aging population are projected to aid the market expansion in the forecast period.
Key Offerings of the Report
- The EMR report gives an overview of the global market for acute pain for the time span of (2019-2025) and (2026 and 2035).
- The report also offers historical (2019-2025) and forecast (2026 and 2035) market information for the drug class, form, indication, distribution channel, and region of the market.
- The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.
About Us
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Contact Us
Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
